Key points: -- The WHO Technical Advisory Group on COVID-19 Vaccine Composition ( TAG-CO-VAC ) held its twice-yearly decision-making meeting in December 2025 to review the evolution of SARS-CoV-2, the performance of currently approved COVID-19 vaccines and the implications for COVID-19 vaccine antigen composition. -- The objective of an update to COVID-19 vaccine antigen composition is to enhance vaccine-induced immune responses to circulating SARS-CoV-2 variants. -- Following this meeting, the TAG-CO-VAC advises vaccine manufacturers that monovalent LP.8.1 is the recommended vaccine antigen. -- The previously recommended JN.1 lineage (JN.1 or KP.2) antigens remain suitable alternatives and vaccination should not be delayed in anticipation of access to vaccines with the LP.8.1 composition. -- Other approaches that demonstrate broad and robust neutralizing antibody responses or efficacy against currently circulating SARS-CoV-2 variants could also be considered. -- Vaccination rema...
Media Monitoring for Signals about Emerging Threats